Blood Cell Therapy

Blood Cell Therapy designates therapeutic applications using blood-derived cellular components including red blood cells, platelets, plasma, or genetically modified blood cells to treat haematological disorders, immune deficiencies, cancers, and other conditions where specific cell populations can restore function or provide targeted therapeutic effects.

The biopharmaceutical industry develops blood cell therapies ranging from established transfusion products to sophisticated genetically engineered cellular medicines. Haematopoietic stem cell transplantation reconstitutes entire blood and immune systems in patients following ablative conditioning. CAR-T cell therapies engineer blood-derived T cells with tumour-targeting chimeric receptors achieving remarkable responses in haematological malignancies. Red blood cell gene therapy corrects haemoglobin disorders including sickle cell disease and beta-thalassaemia. Manufacturing must maintain cellular viability, function, and genetic integrity throughout complex ex vivo processing. As gene editing enables more precise genetic corrections and allogeneic approaches enable off-the-shelf manufacturing, blood cell therapy continues expanding treatment options for previously intractable haematological conditions.